摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-one | 95334-79-5

中文名称
——
中文别名
——
英文名称
1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-one
英文别名
(+/-)-Di-O-methyl-angolensin;2,4,4'-Trimethoxy-alpha-methyldesoxybenzoin
1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-one化学式
CAS
95334-79-5
化学式
C18H20O4
mdl
——
分子量
300.354
InChiKey
GAEVDUCPBKDWJA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    190-195 °C(Press: 0.3 Torr)
  • 密度:
    1.108±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    22
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.28
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-one三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 24.0h, 以90%的产率得到1-(2,4-二羟基苯基)-2-(4-羟基苯基)丙-1-酮
    参考文献:
    名称:
    A Versatile Synthesis of O-Desmethylangolensin Analogues from Methoxy-Substituted Benzoic Acids
    摘要:
    该研究描述了从甲氧基取代的苯甲酸合成 O-去甲基郎格列新(O-DMA)类似物的过程。甲氧基取代的苯甲酸用 2 等量的乙锂处理后得到甲氧基苯丙酮,随后在原甲酸三乙酯中使用 $Pb(OAc)_4/HClO_4$ 通过甲氧基苯基基团的 1,2 重排转化为 2-(甲氧基苯基)丙酸乙酯。用 KOH 进行水解后,2-(甲氧基苯基)丙酸与碳酸二-2-吡啶反应,得到 2-(甲氧基苯基)丙酸 2-吡啶酯,再与甲氧基取代的苯基溴化镁酰化,得到甲氧基-$\{alpha}$-甲基去氧苯甲酸酯。使用三溴化硼对这些化合物的甲氧基进行选择性或完全脱甲基化,可以高产率得到多种 O-DMA 类似物。
    DOI:
    10.5012/jkcs.2014.58.6.569
  • 作为产物:
    参考文献:
    名称:
    Zur Konstitution des Equols
    摘要:
    DOI:
    10.1007/bf01798091
点击查看最新优质反应信息

文献信息

  • Catalytic Alkyne Arylation Using Traceless Directing Groups
    作者:Jung‐Woo Park、Bubwoong Kang、Vy M. Dong
    DOI:10.1002/anie.201804955
    日期:2018.10.8
    to generate enamines, which are then hydrolyzed to either α‐arylphenones or α,α‐diarylketones. This Pd‐catalyzed method overcomes established known pathways to enable the use of amines as traceless directing groups for C−C bond formation.
    通过使用 Pd 0 /Mandyphos,我们实现了炔烃的三组分氨基芳基化以生成烯胺,然后将烯胺水解为 α-芳基苯酮或 α,α-二芳基酮。这种 Pd 催化方法克服了已知的已知途径,能够使用胺作为 C−C 键形成的无痕导向基团。
  • Therapeutic methods and compositions involving isoflavones
    申请人:Novogen Research PTY Limited
    公开号:US20020198248A1
    公开(公告)日:2002-12-26
    Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R 1 is H, or R A CO where R A is C 1-10 alkyl or an amino acid, R 2 is H, OH, or OR B where R B is an amino acid, or CORA where R A is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R 3 is H, COR A where R A is as previously defined, CO 2 R c where R C is C 1-10 alkyl, or COR B where R B is as previously defined, R 4 is H, COR D where R D is H, OH, C 1-10 alkyl or an amino acid, CO 2 R C where R C is as previously defined, COR E where R E is H, C 1-10 alkyl or an amino acid, COOH, COR C where R C is as previously defined, or CONHR E where R E is as previously defined, R 5 is H, COR C where R C is as previously defined, or COR C OR E where R C and R E are as previously defined, and where the two R 5 groups are attached to the same group they are the same or different, R 6 is H or hydroxy C 1-10 alkyl, X is preferably O, but may be N or S, and Y is (h) where R 7 is H, or C 1-10 alkyl. 1
    描述了包含由一般式(1)描述的异黄酮化合物的治疗方法、组合物和食品,其中Z为H,R1为H,或RACO,其中RA为C1-10烷基或氨基酸,R2为H,OH,或ORB,其中RB为氨基酸,或CORA,其中RA如前所定义,W为H,A为H或OH,B从(a),(b),(c)中选择,或W为H,A和B一起形成从(d)中选择的六元环,或W,A和B与它们相关联的基团一起构成(e),或W和A与它们相关联的基团一起构成(f),B为(g),其中R3为H,CORA,其中RA如前所定义,CO2RC,其中RC为C1-10烷基,或CORB,其中RB如前所定义,R4为H,CORD,其中RD为H,OH,C1-10烷基或氨基酸,CO2RC,其中RC如前所定义,CORE,其中RE为H,C1-10烷基或氨基酸,COOH,CORC,其中RC如前所定义,或CONHRE,其中RE如前所定义,R5为H,CORC,其中RC如前所定义,或CORCORE,其中RC和RE如前所定义,两个R5基团连接到相同基团时,它们相同或不同,R6为H或羟基C1-10烷基,X优选为O,但也可以是N或S,Y为(h),其中R7为H或C1-10烷基。
  • [EN] THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES<br/>[FR] PROCEDES THERAPEUTIQUES ET COMPOSITIONS INTEGRANT DES ISOFLAVONES
    申请人:NOVOGEN RESEARCH PTY. LTD.
    公开号:WO1998008503A1
    公开(公告)日:1998-03-05
    (EN) Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, and where the two R5 groups are attached to the same group they are the same or different, R6 is H or hydroxy C1-10alkyl, X is preferably O, but may be N or S, and Y is (h) where R7 is H, or C1-10alkyl.(FR) L'invention concerne des procédés thérapeutiques, des compositions et des produits alimentaires de la formule (I) dans laquelle Z est H, R1 est H ou RACO, RA étant alkyle C1-10 ou un aminoacide, R2 est H, OH ou ORB, RB étant un aminoacide, ou CORA, RA étant comme précédemment défini; W est H; A est H ou OH; B est sélectionné dans le groupe constitué par (a), (b), (c); W est H et A et B forment ensemble un noyau à six chaînes sélectionné dans le groupe constitué par (d); W, A et B, considérés dans les groupes auxquels ils sont associés, comprennent (e); W et A, considérés ensemble dans les groupes auxquels ils sont associés, comprennent (f) et B est (g); R3 est H, CORA, RA étant comme précédemment défini, CO2RC, RC étant alkyle C1-10, ou CORB, RB étant comme précédemment défini; R4 est H, CORD, RD étant H, OH, alkyle C1-10 ou un aminoacide, CO2RC, RC étant comme précédemment défini, CORE, RE étant H, alkyle C1-10 ou un aminoacide, COOH, CORC, RC étant précédemment défini, ou CONHRE, RE étant comme précédemment défini; R5 est H, CO2RC, RC étant comme précédemment défini, ou CORCORE, RC et RE étant comme précédemment définis, et les deux groupes R5 étant liés au même groupe avec lequel ils sont égaux ou différents, R6 est H ou hydroxy-alkyl C1-10; X est de préférence O, mais peut être N ou S, et Y est (h), R7 étant H ou alkyle C1-10.
    描述了包含一般式(I)所描述的异黄酮化合物的治疗方法、组合物和食品。其中,Z为H,R1为H或RACO,RA为C1-10烷基或氨基酸,R2为H、OH或ORB,RB为氨基酸或CORA,RA如前所述,W为H,A为H或OH,B选自(a)、(b)、(c),或W为H,A和B结合形成选择自(d)的六元环,或W、A和B与其相关联的基团组成(e),或W和A与其相关联的基团组成(f),B为(g),其中R3为H、CORA,RA如前所述,CO2RC,RC为C1-10烷基,或CORB,RB如前所述,R4为H、CORD,RD为H、OH、C1-10烷基或氨基酸,CO2RC,RC如前所述,CORE,RE为H、C1-10烷基或氨基酸,COOH,CORC,RC如前所述,或CONHRE,RE如前所述,R5为H、CO2RC,RC如前所述,或CORCORE,RC和RE如前所述,且两个R5基团连接到同一基团时相同或不同,R6为H或羟基C1-10烷基,X优选为O,但也可以为N或S,Y为(h),其中R7为H或C1-10烷基。
  • THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ISOFLAVONES
    申请人:KELLY Graham Edmund
    公开号:US20080287528A1
    公开(公告)日:2008-11-20
    Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (1), in which Z is H, R 1 is H, or R A CO where R A is C 1-10 alkyl or an amino acid, R 2 is H, OH, or OR B where R B is an amino acid, or COR A where R A is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R 3 is H, COR A where R A is as previously defined, CO 2 R C where R C is C 1-10 alkyl, or COR B where R B is as previously defined, R 4 is H, COR D where R D is H, OH, C 1-10 alkyl or an amino acid, CO 2 R C where R C is as previously defined, COR E where R E is H, C 1-10 alkyl or an amino acid, COOH, COR C where R C is as previously defined, or CONHR E where R E is as previously defined, R 5 is H, CO 2 R C where R C is as previously defined, or COR C OR E where R C and R E are as previously defined, and where the two R 5 groups are attached to the same group they are the same or different, R 6 is H or hydroxy C 1-10 alkyl, X is preferably O, but may be N or S, and Y is (h) where R 7 is H, or C 1-10 alkyl.
    本文描述了治疗方法、组合物和食品,其中包含一般式(1)所描述的异黄酮化合物,其中Z为H,R1为H或RACO,其中RA为C1-10烷基或氨基酸,R2为H、OH或ORB,其中RB为氨基酸,或CORA,其中RA如先前定义,W为H,A为H或OH,B选自(a)、(b)、(c),或W为H,A和B结合形成六元环,选自(d),或W、A和B与它们相关的基团组成(e),或W和A与它们相关的基团组成(f),B为(g),其中R3为H,CORA,其中RA如先前定义,CO2RC,其中RC为C1-10烷基,或CORB,其中RB如先前定义,R4为H,CORD,其中RD为H、OH、C1-10烷基或氨基酸,或CO2RC,其中RC如先前定义,CORE,其中RE为H、C1-10烷基或氨基酸,或COOH,CORC,其中RC如先前定义,或CONHRE,其中RE如先前定义,R5为H,CO2RC,其中RC如先前定义,或CORCORE,其中RC和RE如先前定义,且当两个R5基团连接到同一基团时,它们相同或不同,R6为H或羟基C1-10烷基,X优选为O,但也可以为N或S,Y为(h),其中R7为H或C1-10烷基。
  • Foxall,C.D.; Morgan,J.W.W., Journal of the Chemical Society, 1963, p. 5573 - 5575
    作者:Foxall,C.D.、Morgan,J.W.W.
    DOI:——
    日期:——
查看更多

同类化合物

安哥拉紫檀素 2-羟基-3-苯基苯丙酮 1-(2,4-二羟基苯基-3,5-d2)-2-(4-羟基苯基-3,5-d2)丙烷-1-酮-2-d1 1-(2,4-二羟基苯基)-2-(4-羟基苯基)丙-1-酮 1-(1-羟基萘-2-基)-2-甲基-2-苯基丙烷-1-酮 1-(2-hydroxy-5-methylphenyl)-3-(naphthalen-1-yl)-2-phenylpropan-1-one 2,4,5,4'-tetramethoxy-α-methyldesoxybenzoin 1-[2-(1-hydroxynaphthyl)]-2-phenyl-1-propanone 1-(4-(cyc lohexyloxy)-2-methoxyphenyl)-2-(3,4-dimethoxyphenyl)propan-1-one 2-(3,4-dimethoxyphenyl)-1-(4-hydroxy-2-methoxyphenyl)propan-1-one 1-(2-Hydroxy-4-methoxyphenyl)-2-(4-hydroxyphenyl)propan-1-one 1-(2-methoxyphenyl)-2-phenylpropan-1-one 2-(2-fluorophenyl)-1-(2-methoxy-4-(piperidin-1-yl)phenyl)propan-1-one (-)-angolensin (-)-angolensin-4-methyl ether 1-(2-methoxyphenyl)-2-phenyl-2-(trimethylsilyloxy)propan-1-one 1-(2,5-dimethoxy-4-methylphenyl)-2-phenylpropan-1-one (+/-)-1-<2,5-Dimethyl-phenyl>-2-phenyl-propan-1-on 1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)-[1,2,3-(13)C3]propan-1-one 1,2-bis(2-hydroxybenzoyl)-1-propanone 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)-2-methylpropan-1-one (+/-)-2-<2,4-Bis(methoxymethoxy)phenyl>-1-<2-hydroxy-4-(methoxymethoxy)phenyl>propan-1-on 1-(2-hydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)-2-methylpropan-1-one 1-(2-hydroxy-4-methoxyphenyl)-2-(4-methoxyphenyl)-2-methylpropan-1-one 1-(2-hydroxy-4-methoxyphenyl)-2-phenylpropan-1-one 1-(2-hydroxyphenyl)-2-(2-hydroxy-4-methoxyphenyl)-1-propanone 2-hydroxy-3,4-dimethoxy-α-C-methoxydesoxybenzoin (R)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 1-(2,5-dihydroxy-4-methoxyphenyl)-2-(4'-hydroxyphenyl)-1-propanone 1-(5-Bromo-2-hydroxyphenyl)-2-(2-nitrophenyl)propan-1-one 1-(2,5-dihydroxy-4-methoxyphenyl)-2-phenyl-1-propanone 1-(2,4-Dihydroxyphenyl)-2-phenylpropan-1-one 1-(2,3,4-trihydroxyphenyl)-2-phenyl-1-propanone (S)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one Ethyl 4-[1-[4-(dimethylamino)-2-hydroxyphenyl]-1-oxopropan-2-yl]benzoate 2-[[2-(2-Methyl-2-phenylpropanoyl)phenoxy]methoxy]propyl benzoate (2S)-1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one 1-[2,4-Bis(trimethylsiloxy)phenyl]-2-[(4-trimethylsiloxy)phenyl]propan-1-one 1-(2,4-dimethoxyphenyl)-2-(4-methoxyphenyl)propan-1-one (+/-)-Di-O-acetyl-angolensin 4'-hydroxy-2,4-dimethoxy-α-methyldeoxybenzoin 1-(2,3,4-dihydroxyphenyl)-2-(4'-hydroxyphenyl)-1-propanone 1-(2,4-Dihydroxyphenyl)-2-(3-hydroxy-4-methoxyphenyl)propan-1-one 2-(4-Methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one 1-(2,4-Dihydroxyphenyl)-2-(3,5-dimethoxyphenyl)propan-1-one 1-[4-[(1,6-dimethyl-4-propan-2-yl-3,4,4a,7,8,8a-hexahydro-2H-naphthalen-1-yl)oxy]-2-hydroxyphenyl]-2-(4-methoxyphenyl)propan-1-one 1-(2,4-Dihydroxy-5-methoxyphenyl)-2-(4-hydroxyphenyl)propan-1-one (+/-)-4-O-methylangolensin